Royal Fund Management LLC Has $1.01 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Royal Fund Management LLC boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 2.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 5,382 shares of the life sciences company’s stock after acquiring an additional 120 shares during the quarter. Royal Fund Management LLC’s holdings in Illumina were worth $1,009,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. 180 Wealth Advisors LLC grew its position in Illumina by 112.2% in the 2nd quarter. 180 Wealth Advisors LLC now owns 4,323 shares of the life sciences company’s stock valued at $813,000 after purchasing an additional 2,286 shares during the period. Capital Investment Services of America Inc. grew its position in Illumina by 7.6% in the 2nd quarter. Capital Investment Services of America Inc. now owns 48,147 shares of the life sciences company’s stock valued at $9,027,000 after purchasing an additional 3,386 shares during the period. Sarasin & Partners LLP grew its position in Illumina by 0.8% in the 2nd quarter. Sarasin & Partners LLP now owns 552,778 shares of the life sciences company’s stock valued at $103,640,000 after purchasing an additional 4,435 shares during the period. Czech National Bank grew its position in Illumina by 1.0% in the 2nd quarter. Czech National Bank now owns 18,715 shares of the life sciences company’s stock valued at $3,509,000 after purchasing an additional 184 shares during the period. Finally, SG Americas Securities LLC grew its position in Illumina by 531.3% in the 2nd quarter. SG Americas Securities LLC now owns 73,144 shares of the life sciences company’s stock valued at $13,714,000 after purchasing an additional 61,558 shares during the period. Institutional investors and hedge funds own 92.17% of the company’s stock.

Illumina Stock Down 2.6 %

ILMN stock opened at $142.41 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.40 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $22.54 billion, a PE ratio of -5.35, a PEG ratio of 7.90 and a beta of 1.12. Illumina, Inc. has a twelve month low of $142.00 and a twelve month high of $248.87. The stock has a 50-day simple moving average of $174.51 and a two-hundred day simple moving average of $197.05.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Wednesday, August 9th. The life sciences company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.02 by $0.30. Illumina had a positive return on equity of 1.97% and a negative net margin of 93.86%. The company had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the previous year, the firm earned $0.57 earnings per share. Illumina’s revenue was up 1.2% on a year-over-year basis. On average, equities analysts predict that Illumina, Inc. will post 0.83 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, SVP Susan H. Tousi sold 500 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $190.08, for a total transaction of $95,040.00. Following the completion of the transaction, the senior vice president now owns 46,022 shares of the company’s stock, valued at $8,747,861.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 1,500 shares of company stock valued at $278,560. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Robert W. Baird reduced their price target on shares of Illumina from $229.00 to $180.00 in a research report on Thursday, August 10th. Citigroup cut their price objective on shares of Illumina from $180.00 to $150.00 and set a “sell” rating on the stock in a report on Thursday, August 10th. Piper Sandler cut their price objective on shares of Illumina from $290.00 to $275.00 and set an “overweight” rating on the stock in a report on Tuesday, August 15th. HSBC lowered their target price on Illumina from $270.00 to $235.00 and set a “buy” rating on the stock in a research note on Monday, August 14th. Finally, Bank of America lowered their target price on Illumina from $230.00 to $210.00 in a research note on Thursday, August 10th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $236.05.

About Illumina

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.